Miromatrix is excited to announce that a pilot study to evaluate the effectiveness of MIRODERM to close difficult to heal diabetic foot ulcers (DFU) that had previously failed other advanced biologic therapies was just published in WOUNDS. The data demonstrated a >40% closure rate in 12 weeks with the average treated wound having been open for >2 years. It is a great article and the basis of our current multicenter prospective clinical study to further demonstrated the ability of MIRODERM to treat these difficult to heal wounds and provide innovative solutions to physicians and patients.
WOUNDS is the most widely read, peer-reviewed journal focusing on wound care and wound research. Wound care leaders and professionals look towards WOUNDS to provide them with the most current in research and practice in this complex field of medicine.
Click to read the article.